SCHEMBL9948355

SCHEMBL9948355

COc1cccc(-c2n[nH]nc2CN2CCC3(CCN(c4nccc(OC)n4)C3)C2=O)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 13/20 0.50
HCRTR2 O43614 13/20 0.50
HTR1A P08908 1/20 0.49
TSPO P30536 1/20 0.49
PDE10A Q9Y233 1/20 0.37
DRD2 P14416 1/20 0.37
DRD4 P21917 1/20 0.37
DRD3 P35462 1/20 0.37
EGLN1 Q9GZT9 1/20 0.35
CRBN Q96SW2 1/20 0.35
USP2 O75604 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
TSHR P16473 1/20 0.34
CASP1 P29466 1/20 0.34
CYP2C19 P33261 1/20 0.34
CASP7 P55210 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9949491 0.96 HCRTR2 (0.56) HCRTR1HCRTR2HTR1ATSPO
SCHEMBL9948694 0.84 HCRTR1 (0.56) HCRTR1HCRTR2HTR1ATSPO
SCHEMBL9948511 0.78 HCRTR2 (0.61) HCRTR1HCRTR2HTR1ATSPOCRBN
SCHEMBL9948755 0.77 HCRTR1 (0.61) HCRTR1HCRTR2USP2ALDH1A1CYP1A2
SCHEMBL9949265 0.76 HCRTR2 (0.60) HCRTR1HCRTR2HTR1ATSPODRD2
SCHEMBL9948869 0.75 HCRTR1 (0.45) HCRTR1HCRTR2HTR1ATSPODRD2
SCHEMBL9950283 0.75 HCRTR1 (0.44) HCRTR1HCRTR2HTR1ATSPOPDE10A
SCHEMBL9948887 0.75 HCRTR2 (0.68) HCRTR1HCRTR2HTR1ATSPO
SCHEMBL9948907 0.74 HCRTR2 (0.83) HCRTR1HCRTR2HTR1ATSPO
SCHEMBL9948754 0.74 HCRTR2 (0.83) HCRTR1HCRTR2HTR1ATSPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012101487-A1 DI/TRI-AZA-SPIRO-C9-C11ALKANES NOVARTIS AG (CH) 2012-08-02 WO claimed
US-20120165331-A1 Di/tri-aza-spiro-C9-C11alkanes AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-06-28 US claimed
WO-2012101487-A1 DI/TRI-AZA-SPIRO-C9-C11ALKANES NOVARTIS AG (CH) 2012-08-02 WO disclosed
WO-2012101487-A1 DI/TRI-AZA-SPIRO-C9-C11ALKANES NOVARTIS AG (CH) 2012-08-02 WO disclosed
US-20120165331-A1 Di/tri-aza-spiro-C9-C11alkanes AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-06-28 US disclosed
US-20120165331-A1 Di/tri-aza-spiro-C9-C11alkanes AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165331-A1 Di/tri-aza-spiro-C9-C11alkanes TACR2, TACR1, AGTR1 HCRTR1 593/4885HCRTR2 607/4885HTR1A 855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.